{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:06:42Z","timestamp":1776722802644,"version":"3.51.2"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,3]]},"DOI":"10.7759\/cureus.104614","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:25:51Z","timestamp":1772551551000},"source":"Crossref","is-referenced-by-count":1,"title":["Psoriasis Flare Following Interleukin-17 (IL-17) Inhibition and Recent Streptococcal Infection: A Case Report Highlighting Management Complexity"],"prefix":"10.7759","author":[{"given":"Puspita","family":"Hassan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths CE","year":"2007","unstructured":"Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007, 370:263-71. 10.1016\/S0140-6736(07)61128-3","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2010.00871.x","article-title":"Clinical course of guttate psoriasis: long-term follow-up study","volume":"37","author":"Ko HC","year":"2010","unstructured":"Ko HC, Jwa SW, Song M, Kim MB, Kwon KS. Clinical course of guttate psoriasis: long-term follow-up study. J Dermatol. 2010, 37:894-9. 10.1111\/j.1346-8138.2010.00871.x","journal-title":"J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S252578","article-title":"Biologic treatments of psoriasis: an update for the clinician","volume":"15","author":"Brownstone ND","year":"2021","unstructured":"Brownstone ND, Hong J, Mosca M, Hadeler E, Liao W, Bhutani T, Koo J. Biologic treatments of psoriasis: an update for the clinician. Biologics. 2021, 15:39-51. 10.2147\/BTT.S252578","journal-title":"Biologics"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.11.006","article-title":"Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine","volume":"26","author":"Warren RB","year":"2008","unstructured":"Warren RB, Griffiths CE. Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. Clin Dermatol. 2008, 26:438-47. 10.1016\/j.clindermatol.2007.11.006","journal-title":"Clin Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2024.02.001","article-title":"Biologics for psoriasis","volume":"42","author":"Wride AM","year":"2024","unstructured":"Wride AM, Chen GF, Spaulding SL, Tkachenko E, Cohen JM. Biologics for psoriasis. Dermatol Clin. 2024, 42:339-55. 10.1016\/j.det.2024.02.001","journal-title":"Dermatol Clin"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong AW","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, et al.. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020, 156:258-69. 10.1001\/jamadermatol.2019.4029","journal-title":"JAMA Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.993057","article-title":"Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review","volume":"14","author":"Wang J","year":"2023","unstructured":"Wang J, Wang C, Liu L, et al.. Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review. Front Immunol. 2023, 14:993057. 10.3389\/fimmu.2023.993057","journal-title":"Front Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.25259\/IJDVL_719_2023","article-title":"Paradoxical psoriasis induced by IL-17 antagonists","volume":"90","author":"Wang Y","year":"2024","unstructured":"Wang Y, Yang F, Wang R, Luo S. Paradoxical psoriasis induced by IL-17 antagonists. Indian J Dermatol Venereol Leprol. 2024, 90:623-31. 10.25259\/IJDVL_719_2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-024-05647-9","article-title":"Paradoxical psoriasis induced by IL-17 inhibitors: a case series of patients with axial spondyloarthritis and a systematic literature review","volume":"44","author":"Chaitidis N","year":"2024","unstructured":"Chaitidis N, Papadopoulou Z, Varvara ST, Panagiotidis M, Katsigianni I, Sakellariou GT. Paradoxical psoriasis induced by IL-17 inhibitors: a case series of patients with axial spondyloarthritis and a systematic literature review. Rheumatol Int. 2024, 44:2659-68. 10.1007\/s00296-024-05647-9","journal-title":"Rheumatol Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000527737","article-title":"New-onset guttate psoriasis: a long-term follow-up study","volume":"239","author":"Galili E","year":"2023","unstructured":"Galili E, Levy SR, Tzanani I, Segal O, Lyakhovitsky A, Barzilai A, Baum S. New-onset guttate psoriasis: a long-term follow-up study. Dermatology. 2023, 239:188-94. 10.1159\/000527737","journal-title":"Dermatology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/12034754241266187","article-title":"Management of guttate psoriasis: a systematic review","volume":"28","author":"Zhou T","year":"2024","unstructured":"Zhou T, Koussiouris J, Kim L, Vender R. Management of guttate psoriasis: a systematic review. J Cutan Med Surg. 2024, 28:577-84. 10.1177\/12034754241266187","journal-title":"J Cutan Med Surg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03052-7","article-title":"Comparative study of paradoxical and classical psoriasis: what are clinical and therapeutic differences?","volume":"316","author":"Demir Y","year":"2024","unstructured":"Demir Y, Ak T, Temiz SN, Engin B. Comparative study of paradoxical and classical psoriasis: what are clinical and therapeutic differences?. Arch Dermatol Res. 2024, 316:216. 10.1007\/s00403-024-03052-7","journal-title":"Arch Dermatol Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-025-01778-y","article-title":"PDE4 inhibitors in psoriasis therapy: current insights and future directions","volume":"33","author":"Sharma A","year":"2025","unstructured":"Sharma A, Pandoh N, Dayal K, et al.. PDE4 inhibitors in psoriasis therapy: current insights and future directions. Inflammopharmacology. 2025, 33:2885-906. 10.1007\/s10787-025-01778-y","journal-title":"Inflammopharmacology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00877-w","article-title":"Apremilast in palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and meta-analysis","volume":"13","author":"Spencer RK","year":"2023","unstructured":"Spencer RK, Elhage KG, Jin JQ, Davis MS, Hakimi M, Bhutani T, Liao W. Apremilast in palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and meta-analysis. Dermatol Ther (Heidelb). 2023, 13:437-51. 10.1007\/s13555-022-00877-w","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52\u00a0weeks: a phase III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul C","year":"2015","unstructured":"Paul C, Cather J, Gooderham M, et al.. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52\u00a0weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015, 173:1387-99. 10.1111\/bjd.14164","journal-title":"Br J Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0191-7","article-title":"Palmoplantar psoriasis and palmoplantar pustulosis: current treatment and future prospects","volume":"17","author":"Raposo I","year":"2016","unstructured":"Raposo I, Torres T. Palmoplantar psoriasis and palmoplantar pustulosis: current treatment and future prospects. Am J Clin Dermatol. 2016, 17:349-58. 10.1007\/s40257-016-0191-7","journal-title":"Am J Clin Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/430510-psoriasis-flare-following-interleukin-17-il-17-inhibition-and-recent-streptococcal-infection-a-case-report-highlighting-management-complexity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:25:52Z","timestamp":1772551552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/430510-psoriasis-flare-following-interleukin-17-il-17-inhibition-and-recent-streptococcal-infection-a-case-report-highlighting-management-complexity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.104614","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,3]]}}}